Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2001030854) ANTIBODY TO HUMAN GASTROINTESTINAL EPITHELIAL TUMOR ANTIGEN RELATED TO ALPHA 6 BETA 4 INTEGRIN
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2001/030854 International Application No.: PCT/SE2000/002082
Publication Date: 03.05.2001 International Filing Date: 26.10.2000
Chapter 2 Demand Filed: 24.04.2001
IPC:
C07K 16/28 (2006.01) ,C07K 16/30 (2006.01) ,G01N 33/574 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
Applicants:
BRODIN, Thomas, N. [SE/SE]; SE (UsOnly)
KARLSTRÖM, Pia, J. [SE/SE]; SE (UsOnly)
OHLSSON, Lennart, G. [SE/SE]; SE (UsOnly)
TORDSSON, M., Jesper [SE/SE]; SE (UsOnly)
KEARNEY, Phillip, P. [AU/SE]; SE (UsOnly)
NILSON, Bo, H., K. [SE/SE]; SE (UsOnly)
ACTIVE BIOTECH AB [SE/SE]; Box 724 S-220 07 Lund, SE (AllExceptUS)
Inventors:
BRODIN, Thomas, N.; SE
KARLSTRÖM, Pia, J.; SE
OHLSSON, Lennart, G.; SE
TORDSSON, M., Jesper; SE
KEARNEY, Phillip, P.; SE
NILSON, Bo, H., K.; SE
Agent:
AWAPATENT AB; Box 5117 S-200 71 Malmö, SE
Priority Data:
9903895-228.10.1999SE
Title (EN) ANTIBODY TO HUMAN GASTROINTESTINAL EPITHELIAL TUMOR ANTIGEN RELATED TO ALPHA 6 BETA 4 INTEGRIN
(FR) NOUVEAUX COMPOSES
Abstract:
(EN) An antibody, or a derivate or a fragment thereof, having a binding structure for a target structure is described. The antibody is displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells. Said binding structure comprises the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158-162 (CDR1), 177-193 (CDR2), 226-238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties. There is also described a target structure displayed in, or on the surface of tumour cells, vaccine compositions, pharmaceutical compositions as well as methods related to human malignant diseases.
(FR) La présente invention concerne un anticorps, l'un de ses dérivés ou l'un de ces fragments, présentant une structure de liaison convenant à une structure cible. Cet anticorps apparaît dans ou à la surface des cellules tumorales de l'épithélium gastro-intestinal humain et dans une sous-population de cellules normales de l'épithélium gastro-intestinal humain. Cette structure de liaison comprend les séquences de CDR (régions déterminantes de complémentarité) de la chaîne légère constituée essentiellement des acides aminés n° 23-33 (CDR1), 49-55 (CDR2) et 88-98 (CDR3) de la séquence d'acides aminés de SEQ ID NO:2, et les séquences CDR de la chaîne lourde constituée essentiellement des acides aminés n° 158-162 (CDR1), 177-193 (CDR2) et 226-283 (CDR3) de la séquence d'acides aminés de SEQ ID NO:2, ou d'autres structures de liaison présentant des propriétés semblables de liaison unique. L'invention concerne également une structure cible apparaissant dans ou à la surface de cellules tumorales, un vaccin, des compositions, des compositions pharmaceutiques, ainsi que des procédés se rapportant aux affections malignes humaines.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)